Your browser doesn't support javascript.
loading
Growth of Very Low Birth Weight Infants Who Received a Liquid Human Milk Fortifier: A Randomized, Controlled Multicenter Trial.
Masoli, Daniela; Mena, Patricia; Dominguez, Angelica; Ramolfo, Pamela; Vernal, Patricia; Pantoja, Miguel Angel; Esparza, Ruth; Hübner, Maria Eugenia; Ríos, Antonio; Faunes, Miriam; Uauy, Ricardo; Tapia, Jose L.
Affiliation
  • Masoli D; Department of Neonatology, School of Medicine, Pontificia Universidad Católica de Chile.
  • Mena P; Division of Neonatology, Department of Pediatrics, Clínica Alemana/ Faculty of Medicine, Clínica Alemana- Universidad del Desarrollo, Chile.
  • Dominguez A; Hospital Dr. Sótero del Río, Department of Neonatology, School of Medicine, Pontificia Universidad Católica de Chile.
  • Ramolfo P; Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile.
  • Vernal P; Division of Neonatology, Hospital Gustavo Fricke, Viña del Mar, Chile.
  • Pantoja MA; Division of Neonatology, Hospital San José, Universidad de Chile.
  • Esparza R; Division of Neonatology, Hospital San Borja- Arriarán, Universidad de Chile.
  • Hübner ME; Division of Neonatology, Hospital Guillermo Grant Benavente, Concepción, Chile.
  • Ríos A; Division of Neonatology, Department of Pediatrics, Clínica Alemana/ Faculty of Medicine, Clínica Alemana- Universidad del Desarrollo, Chile.
  • Faunes M; Division of Neonatology, Clínica Dávila, Chile.
  • Uauy R; School of Nursing, Pontificia Universidad Católica de Chile.
  • Tapia JL; Department of Neonatology, School of Medicine, Pontificia Universidad Católica de Chile.
J Pediatr Gastroenterol Nutr ; 74(3): 424-430, 2022 Mar 01.
Article in En | MEDLINE | ID: mdl-34620759
OBJECTIVES: To evaluate growth (weight, length, head circumference, and knee-heel length [KHL]) in very low birth weight (VLBW) infants (500-1500 g) who received human milk with a liquid fortifier (LHMF) with high protein and fatty acid content versus a traditional powder fortifier (PHMF) for 45 days or until discharge. METHODS: This was a multicenter, randomized, controlled trial. An intention-to-treat analysis was performed to determine adverse events and withdrawal causes. We also performed an efficacy analysis involving the infants who completed at least 2 weeks of study. RESULTS: Of the 158 infants enrolled in the study, 146 completed at least 2 weeks, and 125 completed the entire study. The biodemographic characteristics were similar between groups, with no differences in increments of weight (22.9 vs 22.7 g kg-1 day-1), length (1.03 vs 1.09 cm/week), head circumference (0.91 vs 0.90 cm/week), or KHL (3.6 vs 3.3 mm/week). The KHL increment was greater in infants weighing >1 kg receiving LHMF (3.7 vs 3.2 mm/week, P = 0.027). Although there were no significant differences in serious adverse events, the incidence difference of the composite outcome death/necrotizing enterocolitis between groups warrants attention (1.3% with LHMF and 8.1% with PHMF). CONCLUSION: There were no differences in the overall growth between VLBW infants receiving either fortifier.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Infant, Premature / Milk, Human Type of study: Clinical_trials Limits: Humans / Infant / Newborn Language: En Journal: J Pediatr Gastroenterol Nutr Year: 2022 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Infant, Premature / Milk, Human Type of study: Clinical_trials Limits: Humans / Infant / Newborn Language: En Journal: J Pediatr Gastroenterol Nutr Year: 2022 Document type: Article Country of publication: United States